Investment analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the stock.
Can-Fite BioPharma Trading Up 0.5 %
CANF stock opened at $1.98 on Monday. The firm’s 50-day moving average is $2.16 and its two-hundred day moving average is $2.12. The company has a market capitalization of $7.01 million, a price-to-earnings ratio of -1.11 and a beta of 1.53. Can-Fite BioPharma has a 52 week low of $1.66 and a 52 week high of $3.33.
Can-Fite BioPharma (NYSE:CANF – Get Free Report) last released its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities research analysts predict that Can-Fite BioPharma will post -0.03 earnings per share for the current year.
Institutional Trading of Can-Fite BioPharma
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Read More
- Five stocks we like better than Can-Fite BioPharma
- What is a Special Dividend?
- MarketBeat Week in Review – 4/15 – 4/19
- How to Most Effectively Use the MarketBeat Earnings Screener
- Comprehensive Analysis of PayPal Stock
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.